Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 207

Sort by

Sort Order Select

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski

Blood blood.2024025939.

https://doi.org/10.1182/blood.2024025939

Published: 2024

Includes: Supplemental data

Journal Articles

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Blood (2024) 144 (12): 1284–1289.

https://doi.org/10.1182/blood.2023023639

Published: 2024

Includes: Supplemental data

Journal Articles

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood blood.2024024582.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood (2023) 142 (22): 1871–1878.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

Incidence of Second Primary Malignancies in Medicare-Insured Patients in the US with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Sikander Ailawadhi, Thomas Delea, Aaron Moynahan, Wenzhen Ge, Christian Hampp, Alexi Archambault, Ning Wu, Karen Rodriguez Lorenc, Irene Noguera-Troise, Glenn S. Kroog, Yariv Houvras, Qiufei Ma

Blood (2023) 142 (Supplement 1): 912.

https://doi.org/10.1182/blood-2023-188562

Published: 2023

Journal Articles

Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration

Tyler B. Sandahl, Scott A. Soefje, Ediz S. Calay, Yi Lin, Rafael Fonseca, Sikander Ailawadhi, Ricardo Parrondo, Dee Lin, Bingcao Wu, Eli Silvert, Nina Kim, Corinne Carpenter, Tyler E. Wagner, Jessica Fowler, Laura Hester, Alexander Marshall, Patrick Stoy, Dina Gifkins, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2023-174270

Published: 2023

Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero

Blood (2023) 142 (Supplement 1): 96.

https://doi.org/10.1182/blood-2023-179152

Published: 2023

Journal Articles

Results of an Open-Label Phase 1 Study Repurposing Oral Metformin and Nelfinavir in Combination with Subcutaneous Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Ibrahim Alodhaibi, Sikander Ailawadhi, Gaby E Perez Burbano, Patrick O'Brien, Francis Buadi, Suzanne R. Hayman, Shaji Kunnathu Kumar, Wilson I. Gonsalves

Blood (2023) 142 (Supplement 1): 6733.

https://doi.org/10.1182/blood-2023-182958

Published: 2023

Journal Articles

Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities

Yaw Adu, Saurav Das, Dhaani Ailawadhi, Andre Fernandez, Ricardo Parrondo, Vivek Roy, Taimur Sher, Sean O'Connell, Ahsan Rasheed, Asher A Chanan- Khan, Sikander Ailawadhi

Blood (2023) 142 (Supplement 1): 2418.

https://doi.org/10.1182/blood-2023-189642

Published: 2023

Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Blood (2023) 142 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2023-173849

Published: 2023

Journal Articles

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kunnathu Kumar, Sagar Lonial, Bart Barlogie, Brian GM Durie, Saad Z Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 1066.

https://doi.org/10.1182/blood-2023-181744

Published: 2023

Journal Articles

Advancing Collaboration across the Multiple Myeloma Treatment Journey from Oncology Clinic to CAR T-Cell Center: A Paired Center Transformative Quality Improvement Initiative

Sikander Ailawadhi, Shelby Sullivan, Jeffrey Carter, Cherilyn Heggen

Blood (2023) 142 (Supplement 1): 5074.

https://doi.org/10.1182/blood-2023-173042

Published: 2023

Journal Articles

Early Predictors of Severe Cytopenia Post CAR-T for Identification of Patients for Potential Stem Cell Collection

Blood (2023) 142 (Supplement 1): 6927.

https://doi.org/10.1182/blood-2023-189683

Published: 2023

Journal Articles

Healthcare Resource Utilization and Economic Burden of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel in Earlier-Line Settings in the KarMMa-3 Clinical Trial

Sikander Ailawadhi, November McGarvey, Ken Imanak, Sana Mirza, Pallavi Patwardhan

Blood (2023) 142 (Supplement 1): 3712.

https://doi.org/10.1182/blood-2023-173938

Published: 2023

Journal Articles

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Sireesha Asoori, Rakesh Popat, Joaquín Martínez-Lopez, Efstathios Kastritis, Larissa Brunaldi, Radhika Bansal, Andre De Menezes Silva Corraes, Kwee Yong, Catriona Mactier, Magdalena Corona, Adolfo Jesús Sáez Marín, Despina Fotiou, Meletios Athanasios Dimopoulos, Saurabh Chhabra, Sikander Ailawadhi, Ricardo Parrondo, Thomas Martin, Brian GM Durie, Yi Lin

Blood (2023) 142 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2023-190793

Published: 2023

Journal Articles

Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases

Hans C. Lee, Sundar Jagannath, Devender Dhanda, Teofilia Acheampong, Pallavi Patwardhan, Thomas S. Marshall, Suvina Amin, Tao Gu, Sikander Ailawadhi

Blood (2023) 142 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2023-173661

Published: 2023

Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Blood (2023) 142 (Supplement 1): 1028.

https://doi.org/10.1182/blood-2023-178933

Published: 2023

Journal Articles

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Blood (2023) 142 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2023-179940

Published: 2023

Journal Articles

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

Blood (2023) 142 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2023-182874

Published: 2023

Journal Articles

First Report on the Effects of Lisaftoclax (APG-2575) in Combination with Novel Therapeutic Regimens in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (Amyloid Light-Chain [AL]) Amyloidosis

Sikander Ailawadhi, Asher A. Chanan-Khan, Costas K. Yannakou, Simon Gibbs, Jack Khouri, Zi Chen, Huanshan Guo, Mingyu Li, Mohammad Ahmad, Cunlin Wang, Dajun Yang, Yifan Zhai

Blood (2023) 142 (Supplement 1): 2016.

https://doi.org/10.1182/blood-2023-188122

Published: 2023

NARROW

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Incidence of Second Primary Malignancies in Medicare-Insured Patients in the US with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Results of an Open-Label Phase 1 Study Repurposing Oral Metformin and Nelfinavir in Combination with Subcutaneous Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Advancing Collaboration across the Multiple Myeloma Treatment Journey from Oncology Clinic to CAR T-Cell Center: A Paired Center Transformative Quality Improvement Initiative

Early Predictors of Severe Cytopenia Post CAR-T for Identification of Patients for Potential Stem Cell Collection

Healthcare Resource Utilization and Economic Burden of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel in Earlier-Line Settings in the KarMMa-3 Clinical Trial

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

First Report on the Effects of Lisaftoclax (APG-2575) in Combination with Novel Therapeutic Regimens in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (Amyloid Light-Chain [AL]) Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only